China Cell Therapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- More Than 400 Cell Therapies Are In Clinical Trials In China
- 2 Cell Therapies Are Commercially Approved
- Insight on More Than 25 Cell Therapies Proprietary Technologies Developed By Chines Companies
- China Cell Therapy Market Opportunity Assessment
- Insight On More Than 400 Cell Therapies In Clinical Trials By Phase, Indication, Company
- Analysis On Pricing & Reimbursement Framework
- Insight On Key Chinese Pharmaceutical Companies Involved In R&D OF Cell Therapies
Download Report: https://www.kuickresearch.com/report-china-cell-therapy-market
With consistent efforts made by the pharmaceutical companies to encourage development of novel drugs and therapies, China has now entered the cell therapy market and is actively competing with its western counterparts. This has been further aided by the technological developments and creation of platforms which have made the process easier. Taking this a step further, the researchers and drug developers in the country are now also focusing on the developing allogeneic cell therapies which will conquer some limitations imposed by autologous cell therapies. The research R&D sector of the country has been evolving as a rapid rate and is bound to give tough competition to the major global pharmaceutical markets in the coming time.
China’s entry in this pipeline has been a remarkable milestone for the country. It was marked by the approval of Axicabtagene Ciloleucel (FKC876) and Relmacabtagene Autoleucel (Carteyva) by its regulatory approval body, National Medical Products Administration in 2021. Both therapies were made through collaborations between a foreign company and a local company which, nevertheless, was an important event for the region’s pharmaceutical market. The approval of these two cell therapies definitely gave a boost to the region’s cell therapy R&D, which had been growing lousily because of the lack of proper government outlines.
After the US, China is being seen as a reliable abode for conducting the development and clinical trials of cell therapies. This is evident from the clinical trials database according to which more than 2000 clinical trials are being conducted in the region. Most of these are focused on CAR – T therapies. Reportedly, more than 50% of the registered clinical trials being conducted worldwide are based in China which warrants its position as the leader of CAR – T therapies of the world. Apart from T cells, researchers in China are also evaluating the safety and efficacy of CAR – NK (natural killer cells), CAR-M (macrophage) and TCR- T (T cell receptor-engineered T cell therapy), all of which have showed promising results, providing hope for the global cell therapy market.
The region’s cell therapy landscape is occupied by numerous companies which are developing new CAR cell therapies, including Cellular Biomedicine Group, Hrain Biotechnology, Hangzhou Imbioray Biomedicine and Yake Biotechnology. The increasing number of companies entering the pipeline has brought in major improvements with them in terms of the efficacy and targeting ability of newer CAR cell therapies. For instance, some novel CAR-T cell therapies have entered pre-clinical development and clinical trials which have dual targeting abilities. These CAR-T cells can simultaneously target two antigens expressed solely on tumors, generating rapid antitumor effects in in vivo. They also protect the cells upon tumor re-challenge and prevent tumors from escaping by lower antigen expression because these CAR-T cells are multispecific.
Additionally, the government has put in efforts to align its regulations with the development of novel therapies to encourage more companies to develop cell therapies and other novel therapies for cancer treatment and to allow a comfortable market entry of these therapies. Moreover, because cell therapies are expensive treatments, their addition into the government’s reimbursement policies can play an important role in further pushing the entry and development of newer cell therapies with exceptional efficacy and targeting abilities.
Once known for being the largest producer of low – quality drugs, China has now emerged as one of the most important regions to contribute significantly to the global pharmaceutical landscape. Since it is home to a major portion of the ongoing clinical trials, it is anticipated that the Chinese cell therapy market will come up with several key developments in the coming years, especially after the surge in partnerships being seen in recent years with foreign companies wanting to enter the tightly-regulated market of the country.